Werner SC. Classification of thyroid disease. Report of the committee on nomenclature. The American Thyroid Association I. J Clin Endocrinol Metab. 1969;29:860–2. https://doi.org/10.1210/jcem-29-6-860.
Monaco F. Classification of thyroid diseases. In: Monaco F, et al., editors. Thyroid diseases: clinical fundamentals and therapy. Boca Raton, FL: CRC; 1993. p. 3–11.
Davies TF, Amino N. A new classification for human autoimmune thyroid disease. Thyroid. 1993;3:331–3.
Weetman AP. Graves’ disease. N Engl J Med. 2000;343:1236–48.
Zhang J, Zhao L, Ga Y, et al. A classification of Hashimoto’s thyroiditis based on immunohistochemistry for IgG4 and IgG. Thyroid. 2014;24:364–70. https://doi.org/10.1089/thy.2013.0211.
Kottahachchi D, Topliss DJ. Immunoglobulin G4-related thyroid diseases. Eur Thyroid J. 2016;5:231–9. https://doi.org/10.1159/000452623.
Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43:661–72.
Mammen JS, Ghazarian SR, Rosen A, Ladenson PW. Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C. Thyroid. 2013;23:1151–8. https://doi.org/10.1089/thy.2012.0565.
Mammen JS, Ghazarian SR, Pulkstenis E, et al. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex. J Clin Endocrinol Metab. 2012;97:3270–6. https://doi.org/10.1210/jc.2012-1026.
Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab. 2012;97:334–42. https://doi.org/10.1210/jc.2011-2576.
Takeshima K, Inaba H, Ariyasu H, et al. Clinicopathological features of Riedel’s thyroiditis associated with IgG4-related disease in Japan. Endocr J. 2015;62:725–31. https://doi.org/10.1507/endocrj.EJ15-0175.
Hennessey JV. Clinical review: Riedel’s thyroiditis: a clinical review. J Clin Endocrinol Metab. 2011;96:3031–41. https://doi.org/10.1210/jc.2011-0617.
Haugen BR, Nawaz S, Cohn A, et al. Secondary malignancy of the thyroid gland: a case report with review of the literature. Thyroid. 1994;4:297–300.
RA DL, Lloyd RV, Heitz PU, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.
Shaw JH, Holden A, Sage M. Thyroid lymphoma. Br J Surg. 1989;76:895–7.
Tseleni S, Arvanitis D, Kakaviatos N, et al. Primary myxoid chondrosarcoma of the thyroid gland. Arch Pathol Lab Med. 1988;112:94–6.
Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinoma of the thyroid. Endocr J. 2009;56:177–19.2.
Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle cytology. Thyroid. 2006;16:47–53.
Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1–7.
Tallini G, Tuttle RM, Ghossein RA. The history of the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2017;102(1):15–22.
Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Med Pathol. 2011;24:1545–52.
Williams ED. Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol. 2000;8:181–3.
Sakamoto A, Kasai A, Sugano H. Poorly differentiated carcinoma of thyroid. A clinicopathologic entity for a high risk group of papillary and follicular carcinomas. Cancer. 1983;52:1849–55.
Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans’ “wuchernde Struma”. Am J Surg Pathol. 1984;8:655–68.
Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma; the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256–64.
Volante M, Bussolati G, Papotti M. The story of poorly differentiated thyroid carcinoma: from Langhans’ description to the Turin proposal via Juan Rosai. Semin Diagn Pathol. 2016;33:277–83.
Baloch Z, Livolsi VA, Tondon R. Aggressive variants of follicular cell derived thyroid carcinoma; the so called “real thyroid carcinomas”. J Cin Pathol. 2013;66:733–43.
Kakudo K, Tang W, Ito Y, et al. Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. J Clin Pathol. 2004;57:1041–6.
Bai Y, Kakudo K, Li Y, et al. Subclassification of non-solid type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci. 2008;99:1908–15.
Ito Y, Hirokawa M, Uruno T, et al. Prevalence and biologic behavior of variants of papillary thyroid carcinoma: experience at a single institute. Pathology. 2008;40:617–22.
Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. Am J Surg Pathol. 2010;34:44–52.
Kato H, Yamashita K, Enomoto T, et al. Classification and general considerations of thyroid cancer. Ann Clin Pathol. 2015;3:1045–53.
Sak SD. Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor. Turk Patoloji Derg. 2015;31:34–47.
Motosugi U, Murata S, Nagata K, et al. Thyroid papillary carcinomas with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid. 2009;19:535–7.
Lino-Silvia LS, Dominguez-Malagon HR, Caro-Sanchez CH, et al. Thyroid gland papillary Ca with “micropapillary pattern”, a recently recognized poor prognostic finding: clinicopathologic and survival analysis of 7 cases. Hum Pathol. 2012;43:1596–600.
Sugitani I, Toda K, Yamamoto N, et al. Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in a iodide-sufficient country. World J Surg. 2010;34:1265–73.
Shi X, Liu R, Basolo F, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab. 2016;101:264–74.
Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical- pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120:71–7.
Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99:276–85.
Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol. 2005;16:163–72.
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma. JAMA Oncol. 2016;2(8):1023–9.
Ganly I, Wang L, Tuttle RM, et al. Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. Hum Pathol. 2015;46:657–64.
Akslen LA, LiVolsi VA. Prognostic significance of histological grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88:1902–8.
Rivera M, Ricarte-Filho J, Patel S, et al. Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Hum Pathol. 2010;41:172–80.
Gnemmi V, Renaud F, DoCao CD, et al. Poorly differentiated thyroid carcinomas: application of Turin proposal provides diagnostic results similar to those from assessment of high-grade features. Histopathology. 2014;64:263–73.
Xu B, Ibrahimpasic T, Wang L, Sabra MM, et al. Clinicopathologic features of fatal non-anaplastic follicular cell-derived thyroid carcinomas. Thyroid. 2016;26(11):1588–97.
Xu B, Wang L, Tuttle RM, Ganly I, Ghossein R. Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. Hum Pathol. 2015;46:1789–98.
Stojadinovic A, Ghossein RA, Hoos A, et al. Hurthle cell carcinoma: a critical histopathological appraisal. J Clin Oncol. 2001;19:2616–25.
Ito Y, Hirokawa M, Miyauchi A, et al. Diagnostic and surgical indications of oxyphilic follicular tumors in Japan: surgical specimens and cytology. Endocr J. 2016;63(11):977–82.
Kakudo K, Bai Y, Katayama S, et al. Classification of thyroid follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute. Pathol Int. 2009;59:359–67.
Kakudo K, Bai Y, Liu Z, et al. Classification of thyroid follicular cell tumors: with special reference to borderline lesions. Endocr J. 2011;59:1–12.
Kakudo K, Wakasa T, Ohta Z, et al. Prognostic classification of thyroid follicular cell tumors using Ki 67 labelling index risk stratification of thyroid follicular cell carcinomas. Endocr J. 2015;62:1–12.
Niemeier LA, Kuffner Akatsu H, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012;118:2069–77.
Wojakowska A, Chekan M, Marczak L, et al. Detection of metabolites discriminating subtypes of thyroid cancer: molecular profiling of FFPE samples using the GC/MS approach. Mol Cell Endocrinol. 2015;417:149–57.
Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690–4.
Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–7.
Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646–56.
Giordano TJ. Follicular cell thyroid neoplasia: insights from genomics and the cancer genome atlas research network. Curr Opin Oncol. 2016;28:1–4.
Pratilas CA, Taylor BS, Ye Q, et al. (V600)BRAF is associated with disable feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009;106:4519–24.
Guerra A, Sapio MR, Marotta V, et al. The primary occurrence of BRAF(V600) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:517–24.
Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013b;20:603–10.
Hsiao SJ, Nikiforov YE. Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer. 2014;21:301–13.
Pierlorenzo P, Battista S, Pierantoni GM, Fusco A. Deregulation of micro RNA expression in thyroid neoplasias. Nat Rev Endocrinol. 2014;10:88–101.
Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56:89–97.
Xing M, Alzahrani AS, Carson KA, Viola D, et al. Association between BRAF V600 mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493–501.
Torregrossa L, Viola D, Sensi E, et al. Papillary thyroid carcinoma with rare exon 15 BRAF mutation has indolent behavior: a single-institution experience. J Clin Endocrinol Metab. 2016;101:4413–20.
Pratilas CA, Solit DB. Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials. 2007;2:121–34.
Leboeuf R, Baumgartner JE, Benezra M, et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 2008;93:2194–201.
Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92:2840–3.
Farndon JR, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct entity. Br J Surg. 1986;73:278–81.
Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MENA and MEN 2B. Science. 1995;267:381–3.
Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA. 1996;276:1575–9.
Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab. 2001;86:1104–9.